Here's What Markets Have Missed By Overlooking The VBI Vaccines CMV News

So, in this instance, the vaccine is called VBI-1501A and – as mentioned – it is targeting CMV. Specifically, the company is trying to develop VBI-1501A as a preventative vaccine. For those not familiar with this space, these sorts of vaccines (as their name suggests) are administered in anticipation of the patient in question becoming infected with, in this case, the CMV virus. The aim is to allow the immune system to develop a collection of antibodies specific to the CMV virus ahead of any infection so that when a patient is infected (if they are, of course) the antibodies required to recognize the virus and to kick start the immune system into attacking and removing it are already in place.

The concept is no different from that which underpins the MMR (measles, mumps, rubella) or the DTP (diphtheria, tetanus, pertussis) vaccines administered to millions of individuals in the US every year. What does differ here, however, is that currently no preventative CMV vaccination is available on the market. This is true despite CMV being one of the most serious and most prevalent newborn infections in the US, with more than 5,000 babies developing problems (ranging from blindness to developmental delays) every year.

The latest data, as mentioned, derives from a phase 1 study and, in particular, a pre-planned interim analysis of said study. The study is primarily set up to address safety (as is generally the case with the sort of early-stage phase I investigations) but is also designed to offer insight into potential efficacy by way of certain immunogenicity signals.

In total, the study enrolled 128 CMV-negative subjects, aged 18-40 years, who were randomized into five arms to receive various dose levels of a modified form of gB, gB-G, with or without the adjuvant alum, or placebo (gB, gB-G here refers to the antigen that the vaccine expresses and that is associated with the CMV virus). The four arms of the study that were given active vaccine received either 0.5mcg of gB-G content with and without alum or 1.0mcg of gB-G content with or without alum.

View single page >> |

Disclosure: The author holds no positions in any of the stocks mentioned in this piece. 

Opinions are my own and I have no business relationship with/am not receiving compensation from any ...

How did you like this article? Let us know so we can better customize your reading experience. Users' ratings are only visible to themselves.


Leave a comment to automatically be entered into our contest to win a free Echo Show.
Kate Hayden 3 years ago Contributor's comment

I thought the news you were going to discuss was the IND issued today for 1901, the brain cancer program. What do you think about that newer news?

David Lamoureux 3 years ago Member's comment

Sci-B-Vac has been in my news feed for a while. I remember the first time I heard of it was at a cocktail party last year. What surprises me is that $VBIV has made remarkable progress on this drug. I think I need to pay it forward and tell my friends about its coming clinic trials this year.

Anastasija Janevska 3 years ago Member's comment

What'd you hear about them? Any insider tips? ;-) $VBIV